Efficacy of Ustekinumab Combined with Partial Enteral Nutrition in Crohn’s Disease

Why It Matters

Integrating PEN with UST offers a practical strategy to boost biologic efficacy and achieve treat‑to‑target remission, addressing a key unmet need in Crohn’s disease management.

Key Takeaways

• UST + PEN achieved 71% endoscopic remission at week 54.
• Combination therapy odds ratio 2.84 for remission after adjustment.
• PEN group reached low CAR (<0.05) in 50% by week 8.
• Effect consistent across demographics, disease location, and behavior subgroups.

Pulse Analysis

Crohn’s disease remains a therapeutic challenge, with biologics such as ustekinumab providing substantial but often incomplete mucosal healing. While UST targets the IL‑12/23 pathway and reduces inflammatory cytokines, up to one‑third of patients experience primary non‑response or loss of response over time. Nutritional status is a critical, yet under‑leveraged, determinant of disease trajectory; malnutrition impairs immune competence and tissue repair, creating a feedback loop that can blunt biologic effectiveness. Partial enteral nutrition (PEN), which supplies at least half of daily caloric needs through specialized formulas, has shown promise in augmenting anti‑TNF outcomes, suggesting a synergistic potential with other biologics.

The recent single‑center cohort adds robust evidence that PEN can amplify ustekinumab’s impact. Patients receiving ≥50% of calories via PEN achieved a 71% endoscopic remission rate at 54 weeks, significantly higher than the 50% observed with UST alone, despite entering the study with worse BMI and CDAI scores. The adjusted odds ratio of 2.84 underscores a genuine, independent effect rather than a confounded association. Early shifts in the C‑reactive protein‑to‑albumin ratio (CAR) indicate that PEN may rapidly attenuate systemic inflammation and improve nutritional reserves, setting the stage for sustained mucosal repair even when clinical symptom scores lag.

For clinicians, these findings suggest that prescribing PEN alongside ustekinumab could become a cost‑effective adjunct to achieve treat‑to‑target goals, especially in patients with baseline malnutrition or high inflammatory burden. However, the retrospective design, single‑center scope, and reliance on documented adherence limit generalizability. Prospective, multicenter trials with standardized PEN protocols and mechanistic biomarker analyses are needed to confirm causality and define optimal dosing. If validated, guideline committees may soon endorse combined nutritional‑biologic regimens as a standard component of Crohn’s disease care, potentially reducing the need for dose escalation or surgery.